Log In
BCIQ
Print this Print this
 

RST-001

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionAdeno-associated virus (AAV) 2 vector activating the channelrhodopsin-2 (ChR2) gene
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$60.0M

$60.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/06/2016

$60.0M

$60.0M

Undisclosed

Get a free BioCentury trial today